Reuters Health Report: September 25, 2017

Klicken Sie hier, um Reuters.com zu abonnieren

Kategorien: Pressemitteilungs Alter: 7 - 13 Jahr 14 - 18 Jahr 19 - 30 Jahr 31 - 64 Jahre 65 Jahre und älter

Laden...

7 jahre vor

Html
Text

Monday, September 25, 2017

Republican bill to repeal Obamacare teeters on edge of collapse

WASHINGTON (Reuters) - The latest Republican effort to repeal former U.S. President Barack Obama's signature healthcare law faced possible defeat this week as several senators in the party voiced concerns about the bill under consideration.

France reaffirms opposition to license renewal for weedkiller glyphosate

PARIS (Reuters) - France reaffirmed on Monday its opposition to plans by the European Commission to extend its approval for the weedkiller product glyphosate, the prime minister's office said.

PureTech's Gelesis says obesity drug achieved weight loss in study

LONDON (Reuters) - PureTech subsidiary Gelesis is moving closer to filing for regulatory approval of its obesity treatment Gelesis100 after results of its latest study, it said on Monday.

Japan health minister to consider U.S. drug firms' views in pricing overhaul

TOKYO (Reuters) - Japan will weigh the concerns of U.S. drug firms in its efforts to complete by year-end a drastic revision of its drug-pricing system, aimed at reining in medical spending and cutting the public burden, the health minister said on Friday.

Native American tribe moves to dismiss Allergan patent case

(Reuters) - A Native American tribe holding patents for drugmaker Allergan Plc on Friday moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

Roche cancer immunotherapy Tecentriq wins EU approval

ZURICH (Reuters) - Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.

Novelion's Aegerion resolves U.S. drug probes for $40 million

BOSTON (Reuters) - Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40.1 million to resolve investigations into its marketing and sales of an expensive cholesterol drug, U.S. authorities said on Friday.

FDA declines to approve J&J arthritis drug sirukumab

(Reuters) - The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Cost of healthy foods may explain heart risks linked to ‘food deserts’

(Reuters Health) - Living in an area with little access to fresh and nutritious foods has been linked to high heart disease risk, but a new study suggests that it’s the inability to afford a healthy diet, rather than access, that’s to blame.

Some youth football drills raise head-impact risk more than others

(Reuters Health) - Several youth football drills expose young athletes to head impacts more frequently and more roughly than others, according to a U.S. study that followed 10- and 11-year-old players for a full season.

Teilen auf

Laden...

Weitere Newsletter von Reuters.com

Laden...

Andere Kategorien anzeigen

Pressemitteilungs

Reuters Health Report: September 25, 2017

Teilen auf

Weitere Newsletter von Reuters.com

Verwandte Newsletter

Andere Kategorien anzeigen